{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-254597","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2026-06-03T11:35:14+00:00","discovered_at":"2026-06-03T11:40:00.242745+00:00","generated_at":"2026-06-03T11:40:07.593316+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Dyne Therapeutics completes enrollment of ACHIEVE registrational cohort with 71 DM1 patients","bullets":["Registrational expansion cohort (REC) enrolled 71 participants; topline data expected Q1 2027.","Potential BLA submission for U.S. Accelerated Approval in Q3 2027 using REC and MAD/LTE data.","Potential U.S. launch of z-basivarsen in H1 2028 if FDA grants Priority Review.","Also pursuing approval pathways outside U.S. for DM1 therapy.","ACHIEVE primary endpoint: change in middle finger myotonia via vHOT at 6 months vs placebo."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-254597","json":"https://secwatch.observer/filing/0001193125-26-254597.json","markdown":"https://secwatch.observer/filing/0001193125-26-254597.md","text":"https://secwatch.observer/filing/0001193125-26-254597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526254597/0001193125-26-254597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526254597/dyn-20260603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T11:40:07.593316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}